Elixir Associates reposted this
💥 Exciting Progress in Obesity Treatment! 💥 Roche's recent $2.7 billion acquisition of Carmot Therapeutics is already paying off. 🌟 In a groundbreaking phase 1 trial, participants achieved an impressive average weight loss of 7.3% in just four weeks using Carmot's oral GLP-1 prospect, CT-996. This result suggests CT-996 can stand toe-to-toe with rivals from Eli Lilly and Pfizer. The trial focused on individuals with obesity but not type 2 diabetes. The 6.1% placebo-adjusted weight reduction achieved highlights the potential impact of CT-996 on the obesity battlefront. Compared to other competitors like Novo Nordisk's oral semaglutide and Lilly's orforglipron, which required much longer periods to show similar results, CT-996's rapid efficacy is noteworthy. 👏 Safety-wise, CT-996 performed well with mostly mild to moderate side effects and no discontinuations due to adverse events. This adds to its promise as a flexible dosing option suitable even when food intake varies. As Roche prepares for further trials to explore both glycemic control and weight maintenance, it's clear that CT-996 could be a game-changer in the obesity treatment landscape. 🌐 #ClinicalResearch #ObesityTreatment #Pharmaceuticals #Roche #Carmot